Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Autoimmune Disease Therapeutics Market

Veterinary Autoimmune Disease Therapeutics Market Size

Report ID: GMI6228
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Veterinary Auto-immune Therapeutics Market Size

Veterinary Auto-immune Therapeutics Market size was valued to be USD 3.1 billion in 2022 and is expected to reach USD 5.2 billion in 2032 with a CAGR of 5.3% from 2023 to 2032 owing to increasing threat of transfer of zoonotic diseases among human, rising incidence of auto-immune diseases in livestock animals, increasing awareness and diagnosis of autoimmune diseases, growing companion animal ownership, increasing expenditure on animal healthcare, and increasing in animal health medicalization rate.

To get key market trends

Download Free Sample

The veterinary auto-immune therapeutics are drugs which are used when the immune system does not work properly in animals and starts to attack the own tissues or organs. Some examples of auto-immune diseases in animals are pemphigus vulgaris, autoimmune haemolytic anemia, canine systemic lupus, rheumatoid arthritis etc. These diseases can occur with no identifiable cause or can result from infections, cancer, or specific drugs. The focus of auto-immune therapeutics is to control the immunological response. They are used to decrease or reduce the symptoms and inflammation, decrease the associated pain, or inhibit the inappropriate immune response.

Veterinary Autoimmune Disease Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2022
Veterinary Autoimmune Disease Therapeutics Market Size in 2022:	USD 3.1 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	5.3%
2032 Value Projection:	USD 5.2 Billion
Historical Data for:	2018 to 2022
No. of Pages:	236
Tables, Charts & Figures:	409
Segments covered:	Therapy Type, Disease, Animal, Distribution Channel, and Region
Growth Drivers:	Increasing threat of transfer of zoonotic diseases among human Rising incidence of auto-immune diseases in livestock animals Increasing awareness and diagnosis of autoimmune diseases Increasing companion animal ownership Increasing in animal health medicalization rate
Pitfalls & Challenges:	High cost of veterinary auto-immune therapies Increase risk of infection due to autoimmune drugs

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market for veterinary auto-immune therapeutics size was worth USD 3.1 billion in 2022 and is set to reach USD 5.2 billion in 2032 with a 5.3% CAGR from 2023 to 2032 driven by the increasing threat of transfer of zoonotic diseases among humans, rising incidence of auto-immune diseases in livestock animals and increasing awareness and diagnosis of autoimmune diseases.

The corticosteroids segment generated USD 1.1 billion in revenue in 2022 and is expected to grow significantly attributed to the increasing demand for corticosteroids as it helps in reducing the severity of symptoms and provide relief to affected animals.

The North America veterinary auto-immune therapeutics market is expected to reach USD 2.2 billion in 2032 with a 5.5% CAGR from 2023-2032 attributed to the large population of companion animals, including dogs, cats, and horses across the region.

Aratana Therapeutics Inc., Pfizer Inc., Vet-Stem Inc., Ambrx Inc., Taconic Biosciences Inc., JBS United, Virbac, Eli Lily and Company, and Jaguar Animal Health Inc. are some of the top enterprises engaged in the industry